Harry W. Findley
- Molecular Biology top 10%
- Oncology top 5%
- Immunology top 5%
- Cancer Research top 10%
- Hematology top 5%
- Co-authors
- Lubing GuMuxiang ZhouNingxi ZhuWilliam G. WoodsAndrew M. YeagerFengzhi LiNianyong ZhuMei Zhou
- Topics
- Acute Lymphoblastic Leukemia research (16 papers)Cancer-related Molecular Pathways (14 papers)Cell death mechanisms and regulation (13 papers)
- Cited by
- OncologyHematologyImmunology
- Partner nations
- United StatesCanadaNorway
In The Last Decade
Harry W. Findley
54 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 91
- Molecular Biology 1.1k
- Oncology 634
- Immunology 447
- Cancer Research 254
- Hematology 237
Countries citing papers authored by Harry W. Findley
This map shows the geographic impact of Harry W. Findley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry W. Findley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry W. Findley more than expected).
Fields of papers citing papers by Harry W. Findley
This network shows the impact of papers produced by Harry W. Findley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry W. Findley. The network helps show where Harry W. Findley may publish in the future.
Co-authorship network of co-authors of Harry W. Findley
This figure shows the co-authorship network connecting the top 25 collaborators of Harry W. Findley. A scholar is included among the top collaborators of Harry W. Findley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry W. Findley. Harry W. Findley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 22 | |
| 2 | 30 | |
| 3 | 43 | |
| 4 | 29 | |
| 5 | Loss of PTEN expression induces NF-kB via PI3K/Akt pathway involving resistance to chemotherapy in acute lymphoblastic leukemia cell lines | 1 |
| 6 | 47 | |
| 7 | 86 | |
| 8 | 48 | |
| 9 | 8 | |
| 10 | 118 | |
| 11 | 67 | |
| 12 | 5 | |
| 13 | 9 | |
| 14 | 3 | |
| 15 | 31 | |
| 16 | 18 | |
| 17 | 17 | |
| 18 | 16 | |
| 19 | 10 | |
| 20 | 17 |
About Harry W. Findley
Harry W. Findley is a scholar working on Hematology, Immunology and Oncology, having authored 54 papers that have together received 1.8k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (16 papers), Cancer-related Molecular Pathways (14 papers) and Cell death mechanisms and regulation (13 papers). The work is most often cited by research in Oncology (634 citations), Hematology (237 citations) and Immunology (447 citations). Harry W. Findley has collaborated with scholars based in United States, Canada and Norway. Frequent co-authors include Lubing Gu, Muxiang Zhou, Ningxi Zhu, William G. Woods, Andrew M. Yeager, Fengzhi Li, Nianyong Zhu, Mei Zhou, Carlos S. Alvarado and Yerun Zhu. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.